DADC
PGNX

D.A. Davidson & Co’s Progenics Pharmaceuticals Inc PGNX Stock Holding History

D.A. Davidson & Co’s Portfolio PGNX Stock Details PGNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-1,000
Closed -$4K – 2516
2016
Q2 		$4K Buy
+1,000
New +$4.83K ﹤0.01% 2176

Other funds holding PGNX

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
PA
Pinnacle Associates New York $7.78B AUM 45.07% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

D.A. Davidson & Co's PGNX Position: Q3 2016 in Review

D.A. Davidson & Co sold out of Progenics Pharmaceuticals Inc (PGNX) in Q3 2016, closing a stake of 1,000 shares — an estimated $4K sold.

D.A. Davidson & Co first reported a position in PGNX in Q2 2016 and held it in 1 quarter. The position peaked at $4K in Q2 2016. 115 funds tracked by Wall St. Rank hold PGNX as of Q3 2016.

  • D.A. Davidson & Co reported no remaining Progenics Pharmaceuticals Inc position as of Q3 2016 after selling out during the quarter.
  • D.A. Davidson & Co sold 1,000 Progenics Pharmaceuticals Inc shares in Q3 2016, an estimated $4K.
  • D.A. Davidson & Co first reported a position in Progenics Pharmaceuticals Inc in Q2 2016 and held it in 1 quarter.
  • D.A. Davidson & Co's Progenics Pharmaceuticals Inc position peaked at $4K in Q2 2016.
  • 115 funds tracked by Wall St. Rank held Progenics Pharmaceuticals Inc as of Q3 2016.

Based on D.A. Davidson & Co's 13F filing for Q3 2016, filed 14 Nov 2016.